# A Systems Hypothesis of Lipopolysaccharide-Induced Vitamin Transport Suppression and Metabolic Reprogramming in Autism Spectrum Disorders: An Open Call for Validation and Therapeutic Translation

**Authors:** Albion Dervishi

PMC · DOI: 10.3390/metabo15060399 · Metabolites · 2025-06-13

## TL;DR

This paper proposes a new hypothesis linking gut bacteria toxins to metabolic issues in autism, suggesting vitamin transport problems may worsen brain energy and development.

## Contribution

Introduces a systems biology framework (PM3) to identify metabolic dysregulation in autism linked to vitamin transport suppression and LPS exposure.

## Key findings

- ASD brains show consistent downregulation of glycolysis and mitochondrial enzymes like PFKM and SUCLA2.
- Multivitamin transporters such as SLC5A6 and SLC19A2 are suppressed in ASD, potentially worsening energy deficits.
- LPS exposure is hypothesized to initiate metabolic reprogramming and mitochondrial dysfunction in ASD.

## Abstract

Background: Autism spectrum disorder (ASD) is increasingly linked to systemic metabolic dysfunction, potentially influenced by gut–brain axis dysregulation, but the underlying mechanisms remain unclear. Methods: We developed Personalized Metabolic Margin Mapping (PM3), a computational systems biology framework, to analyze RNA-seq data from 12 ASD and 12 control postmortem brain samples. The model focused on 158 curated metabolic genes selected for their roles in redox balance, mitochondrial function, neurodevelopment, and gut–brain interactions. Results: Using unsupervised machine learning (Isolation Forest) to detect outlier expression patterns, Euclidean distance, and percent expression difference metrics, PM3 revealed a consistent downregulation of glycolysis (e.g., −5.4% in PFKM) and mitochondrial enzymes (e.g., −12% in SUCLA2). By incorporating cofactor dependency and subcellular localization, PM3 identified a coordinated suppression of multivitamin transporters (e.g., −4.5% in SLC5A6, −3.5% in SLC19A2), potentially limiting cofactor availability and compounding energy deficits in ASD brains. Conclusions: These findings suggest a convergent metabolic dysregulation signature in ASD; wherein the subtle suppression of cofactor-dependent pathways may impair energy metabolism and neurodevelopment. We propose that chronic microbial lipopolysaccharide (LPS) exposure in ASD suppresses vitamin transporter function, initiating mitochondrial dysfunction and transcriptomic reprogramming. Validation in LPS-exposed systems using integrated transcriptomic–metabolomic analysis is warranted.

## Linked entities

- **Genes:** PFKM (phosphofructokinase, muscle) [NCBI Gene 5213], SUCLA2 (succinate-CoA ligase ADP-forming subunit beta) [NCBI Gene 8803], SLC5A6 (solute carrier family 5 member 6) [NCBI Gene 8884], SLC19A2 (solute carrier family 19 member 2) [NCBI Gene 10560]
- **Diseases:** autism spectrum disorder (MONDO:0005258), ASD (MONDO:0006664)

## Full-text entities

- **Genes:** SLC5A6 (solute carrier family 5 member 6) [NCBI Gene 8884] {aka COMNB, NERIB, SMVT, SMVTD, hSMVT}, SLC19A2 (solute carrier family 19 member 2) [NCBI Gene 10560] {aka TC1, THMD1, THT1, THTR1, TRMA}, PFKM (phosphofructokinase, muscle) [NCBI Gene 5213] {aka ATP-PFK, GSD7, PFK-1, PFK-A, PFK1, PFKA}, SUCLA2 (succinate-CoA ligase ADP-forming subunit beta) [NCBI Gene 8803] {aka A-BETA, A-SCS, LINC00444, MTDPS5, SCS-betaA}
- **Diseases:** mitochondrial dysfunction (MESH:D028361), ASD (MESH:D000067877), metabolic dysfunction (MESH:D008659)
- **Chemicals:** LPS (MESH:D008070)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12195403/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12195403/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12195403/full.md

---
Source: https://tomesphere.com/paper/PMC12195403